DD220500A5 - Vorrichtung fuer die extrakorporale behandlung von erkrankten koerperfluessigkeiten - Google Patents
Vorrichtung fuer die extrakorporale behandlung von erkrankten koerperfluessigkeiten Download PDFInfo
- Publication number
- DD220500A5 DD220500A5 DD84263650A DD26365084A DD220500A5 DD 220500 A5 DD220500 A5 DD 220500A5 DD 84263650 A DD84263650 A DD 84263650A DD 26365084 A DD26365084 A DD 26365084A DD 220500 A5 DD220500 A5 DD 220500A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- polymer
- item
- body fluid
- biospecific
- carrier
- Prior art date
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 53
- 239000010839 body fluid Substances 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims description 35
- 229920000642 polymer Polymers 0.000 claims abstract description 99
- 230000001575 pathological effect Effects 0.000 claims abstract description 33
- 239000012636 effector Substances 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 201000010099 disease Diseases 0.000 claims description 43
- 125000006850 spacer group Chemical group 0.000 claims description 22
- -1 alkyl glycidyl ethers Chemical class 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 229920001519 homopolymer Polymers 0.000 claims description 13
- 229920000249 biocompatible polymer Polymers 0.000 claims description 12
- 229920001577 copolymer Polymers 0.000 claims description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 11
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 239000000178 monomer Substances 0.000 claims description 9
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 5
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 108010083674 Myelin Proteins Proteins 0.000 claims description 4
- 102000006386 Myelin Proteins Human genes 0.000 claims description 4
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 4
- 150000003926 acrylamides Chemical class 0.000 claims description 4
- 210000002808 connective tissue Anatomy 0.000 claims description 4
- 108010074605 gamma-Globulins Proteins 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920001296 polysiloxane Polymers 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- JJRUAPNVLBABCN-UHFFFAOYSA-N 2-(ethenoxymethyl)oxirane Chemical class C=COCC1CO1 JJRUAPNVLBABCN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 102000005717 Myeloma Proteins Human genes 0.000 claims description 3
- 108010045503 Myeloma Proteins Proteins 0.000 claims description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical class CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 229920001897 terpolymer Polymers 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 102000006834 complement receptors Human genes 0.000 claims description 2
- 108010047295 complement receptors Proteins 0.000 claims description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical class NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims description 2
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical class C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 238000000034 method Methods 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 210000002381 plasma Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 23
- 239000000306 component Substances 0.000 description 21
- 239000000126 substance Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 15
- 239000012530 fluid Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 230000027455 binding Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 125000000524 functional group Chemical group 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 229920006254 polymer film Polymers 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000004593 Epoxy Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000012503 blood component Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000001613 neoplastic effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000021386 Sjogren Syndrome Diseases 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 238000002616 plasmapheresis Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229920001247 Reticulated foam Polymers 0.000 description 4
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 4
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 4
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 229920000307 polymer substrate Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000007475 hemolytic anemia Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 208000026872 Addison Disease Diseases 0.000 description 2
- 206010060935 Alloimmunisation Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 208000024781 Immune Complex disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010037549 Purpura Diseases 0.000 description 2
- 241001672981 Purpura Species 0.000 description 2
- 208000012322 Raynaud phenomenon Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 206010042276 Subacute endocarditis Diseases 0.000 description 2
- 102000009843 Thyroglobulin Human genes 0.000 description 2
- 108010034949 Thyroglobulin Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 201000003278 cryoglobulinemia Diseases 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000008467 subacute bacterial endocarditis Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 229960002175 thyroglobulin Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- SAHQQCUQWHJOCV-SNAWJCMRSA-N (e)-2-ethenylbut-2-enoic acid Chemical compound C\C=C(/C=C)C(O)=O SAHQQCUQWHJOCV-SNAWJCMRSA-N 0.000 description 1
- FPIGOBKNDYAZTP-UHFFFAOYSA-N 1,2-epoxy-3-(4-nitrophenoxy)propane Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCC1OC1 FPIGOBKNDYAZTP-UHFFFAOYSA-N 0.000 description 1
- VAYTZRYEBVHVLE-UHFFFAOYSA-N 1,3-dioxol-2-one Chemical compound O=C1OC=CO1 VAYTZRYEBVHVLE-UHFFFAOYSA-N 0.000 description 1
- PXGZQGDTEZPERC-UHFFFAOYSA-N 1,4-cyclohexanedicarboxylic acid Chemical compound OC(=O)C1CCC(C(O)=O)CC1 PXGZQGDTEZPERC-UHFFFAOYSA-N 0.000 description 1
- SGNXVBOIDPPRJJ-PSASIEDQSA-N 1-[(1r,6r)-9-azabicyclo[4.2.1]non-4-en-5-yl]ethanone Chemical compound CC(=O)C1=CCC[C@@H]2CC[C@H]1N2 SGNXVBOIDPPRJJ-PSASIEDQSA-N 0.000 description 1
- VOCDJQSAMZARGX-UHFFFAOYSA-N 1-ethenylpyrrolidine-2,5-dione Chemical compound C=CN1C(=O)CCC1=O VOCDJQSAMZARGX-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- IEVADDDOVGMCSI-UHFFFAOYSA-N 2-hydroxybutyl 2-methylprop-2-enoate Chemical compound CCC(O)COC(=O)C(C)=C IEVADDDOVGMCSI-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- UWRZIZXBOLBCON-UHFFFAOYSA-N 2-phenylethenamine Chemical class NC=CC1=CC=CC=C1 UWRZIZXBOLBCON-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 230000010785 Antibody-Antibody Interactions Effects 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000027932 Collagen disease Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 125000004077 D-glutamic acid group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])[H])=O 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108091023046 Deoxyribonucleoprotein Proteins 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010015251 Erythroblastosis foetalis Diseases 0.000 description 1
- 229940124135 Factor VIII inhibitor Drugs 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010051645 Idiopathic neutropenia Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000022435 Light chain deposition disease Diseases 0.000 description 1
- 208000020647 Light chain disease Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010058858 Meningococcal bacteraemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000025047 Non-histaminic angioedema Diseases 0.000 description 1
- 239000004727 Noryl Substances 0.000 description 1
- 229920001207 Noryl Polymers 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 201000006537 Plasmodium malariae malaria Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000034712 Rickettsia Infections Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000000860 Secondary syphilis Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010058028 Shunt infection Diseases 0.000 description 1
- 240000005038 Spathoglottis aurea Species 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 208000013633 acquired hemophilia Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003948 anatoxin Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- PVEOYINWKBTPIZ-UHFFFAOYSA-N but-3-enoic acid Chemical compound OC(=O)CC=C PVEOYINWKBTPIZ-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 108010009717 circulating anticoagulants Proteins 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical compound C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-M ethenesulfonate Chemical compound [O-]S(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-M 0.000 description 1
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000004526 exfoliative dermatitis Diseases 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 208000001031 fetal erythroblastosis Diseases 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000022089 meningococcemia Diseases 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- RQAKESSLMFZVMC-UHFFFAOYSA-N n-ethenylacetamide Chemical compound CC(=O)NC=C RQAKESSLMFZVMC-UHFFFAOYSA-N 0.000 description 1
- KKFHAJHLJHVUDM-UHFFFAOYSA-N n-vinylcarbazole Chemical compound C1=CC=C2N(C=C)C3=CC=CC=C3C2=C1 KKFHAJHLJHVUDM-UHFFFAOYSA-N 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000004880 oxines Chemical group 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 229920002454 poly(glycidyl methacrylate) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920013637 polyphenylene oxide polymer Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004176 reticulum cell Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000005057 thyrotoxicosis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/12—Flow characteristics the flow being spirally in a plane, e.g. against a plane side of a membrane filter element
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Manipulator (AREA)
- Eye Examination Apparatus (AREA)
- Surgical Instruments (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Catching Or Destruction (AREA)
- Materials For Medical Uses (AREA)
- Photographic Processing Devices Using Wet Methods (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49998983A | 1983-06-01 | 1983-06-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD220500A5 true DD220500A5 (de) | 1985-04-03 |
Family
ID=23987585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD84263650A DD220500A5 (de) | 1983-06-01 | 1984-05-31 | Vorrichtung fuer die extrakorporale behandlung von erkrankten koerperfluessigkeiten |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0132534B1 (ja) |
| JP (1) | JPS605167A (ja) |
| KR (1) | KR910004329B1 (ja) |
| AT (1) | ATE65413T1 (ja) |
| AU (2) | AU2883384A (ja) |
| BR (1) | BR8402614A (ja) |
| CA (1) | CA1236738A (ja) |
| DD (1) | DD220500A5 (ja) |
| DE (1) | DE3484831D1 (ja) |
| DK (1) | DK267884A (ja) |
| IL (1) | IL71983A (ja) |
| IN (1) | IN160675B (ja) |
| MX (1) | MX155537A (ja) |
| NO (1) | NO842168L (ja) |
| PL (1) | PL247978A1 (ja) |
| YU (1) | YU93184A (ja) |
| ZA (1) | ZA844121B (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0214392A1 (de) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medizinisches Gerät, insbesondere Filter, Kanüle, Katheter oder Implantat |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061237A (en) * | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
| DE3523616A1 (de) * | 1985-07-02 | 1987-01-15 | Cytomed Medizintechnik | Filter |
| US5474772A (en) * | 1989-08-02 | 1995-12-12 | Cobe Laboratories, Inc. | Method of treatment with medical agents |
| SE9100142L (sv) | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
| DE4113602A1 (de) * | 1991-04-23 | 1992-10-29 | Falkenhagen Dieter Dr Sc Med | Endotoxinadsorber und verfahren zu seiner herstellung |
| US5972102A (en) * | 1996-10-29 | 1999-10-26 | North American Refractories Co. | Hydraulically-bonded monolithic refractories containing a calcium oxide-free binder comprised of a hydratable alumina source and magnesium oxide |
| RU2178313C1 (ru) * | 2000-08-29 | 2002-01-20 | Кутушов Михаил Владимирович | Композиция для экстракорпоральной обработки биологических жидкостей и способ получения магнитоуправляемого сорбента для ее осуществления (варианты) |
| GB0112363D0 (en) * | 2001-05-21 | 2001-07-11 | Allied Therapeutics Ltd | Method and apparatus for treating biological fluids |
| US10905818B2 (en) * | 2014-03-31 | 2021-02-02 | Zoll Medical Corporation | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
| RU2018134142A (ru) * | 2016-03-08 | 2020-04-08 | Сайтосорбентс Корпорейшн | Применение гранулированного сорбента на основе гемосовместимого пористого полимера для удаления молекулярных структур, ассоциированных с патогенами, и молекулярных структур, ассоциированных с повреждениями |
| CA3154382A1 (en) | 2019-09-13 | 2021-03-18 | The Trustees Of Indiana University | Devices and methods for modulating adma in blood |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3794584A (en) * | 1970-04-09 | 1974-02-26 | Rohm & Haas | Removal of poisons and drugs from blood |
| SE383258B (sv) * | 1970-12-11 | 1976-03-08 | V H Hyden | Anordning for att i terapeutiskt syfte selektivt och under kontroll avskilja icke onskade bestandsdelar ur blod |
| CS167530B1 (en) * | 1972-03-29 | 1976-04-29 | Jiri Coupek | Method of insoluble biologically active compounds preparation |
| US3826678A (en) * | 1972-06-06 | 1974-07-30 | Atomic Energy Commission | Method for preparation of biocompatible and biofunctional materials and product thereof |
| US3896217A (en) * | 1973-03-19 | 1975-07-22 | Summa Corp | Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent |
| JPS56145858A (en) * | 1980-04-15 | 1981-11-12 | Unitika Ltd | Purifier for body fluid |
| JPS5743744A (en) * | 1980-08-26 | 1982-03-11 | Toyo Boseki | Peculiar adsorber |
| CA1177751A (en) * | 1980-12-09 | 1984-11-13 | Shuntaro Hosaka | Immunoparticles and process for preparing same |
| US4381004A (en) * | 1981-01-15 | 1983-04-26 | Biomedics, Inc. | Extracorporeal system for treatment of infectious and parasitic diseases |
| DE3109123A1 (de) * | 1981-03-11 | 1982-09-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Verfahren zur kovalenten immobilisierung von biologischen detoxikationssystemen auf kuenstlichen oberflaechen |
| US4430229A (en) * | 1981-05-22 | 1984-02-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Immune adsorbent and adsorbing device |
| JPS58173553A (ja) * | 1982-04-01 | 1983-10-12 | 旭化成株式会社 | 血漿浄化装置 |
| JPS5922557A (ja) * | 1982-07-30 | 1984-02-04 | 旭化成株式会社 | エンドトキシン血症治療器 |
| JPS59168858A (ja) * | 1983-03-17 | 1984-09-22 | 旭化成株式会社 | 糖含有物質の吸着浄化器 |
-
1984
- 1984-05-09 CA CA000453903A patent/CA1236738A/en not_active Expired
- 1984-05-25 AT AT84105986T patent/ATE65413T1/de not_active IP Right Cessation
- 1984-05-25 DE DE8484105986T patent/DE3484831D1/de not_active Expired - Lifetime
- 1984-05-25 EP EP84105986A patent/EP0132534B1/en not_active Expired - Lifetime
- 1984-05-30 BR BR8402614A patent/BR8402614A/pt unknown
- 1984-05-30 IN IN398/MAS/84A patent/IN160675B/en unknown
- 1984-05-30 ZA ZA844121A patent/ZA844121B/xx unknown
- 1984-05-30 NO NO842168A patent/NO842168L/no unknown
- 1984-05-30 DK DK267884A patent/DK267884A/da not_active Application Discontinuation
- 1984-05-30 AU AU28833/84A patent/AU2883384A/en not_active Abandoned
- 1984-05-31 IL IL71983A patent/IL71983A/xx unknown
- 1984-05-31 YU YU00931/84A patent/YU93184A/xx unknown
- 1984-05-31 DD DD84263650A patent/DD220500A5/de not_active IP Right Cessation
- 1984-05-31 MX MX201511A patent/MX155537A/es unknown
- 1984-05-31 JP JP59112178A patent/JPS605167A/ja active Granted
- 1984-05-31 KR KR1019840003016A patent/KR910004329B1/ko not_active Expired
- 1984-05-31 PL PL24797884A patent/PL247978A1/xx unknown
-
1988
- 1988-10-10 AU AU23586/88A patent/AU610258B2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0214392A1 (de) * | 1985-07-02 | 1987-03-18 | Omni Medical Limited | Medizinisches Gerät, insbesondere Filter, Kanüle, Katheter oder Implantat |
Also Published As
| Publication number | Publication date |
|---|---|
| DK267884D0 (da) | 1984-05-30 |
| EP0132534A3 (en) | 1985-12-18 |
| KR910004329B1 (ko) | 1991-06-26 |
| IL71983A (en) | 1989-08-15 |
| ATE65413T1 (de) | 1991-08-15 |
| IN160675B (ja) | 1987-07-25 |
| CA1236738A (en) | 1988-05-17 |
| DK267884A (da) | 1984-12-02 |
| EP0132534A2 (en) | 1985-02-13 |
| ZA844121B (en) | 1984-12-24 |
| YU93184A (en) | 1988-02-29 |
| AU610258B2 (en) | 1991-05-16 |
| DE3484831D1 (de) | 1991-08-29 |
| MX155537A (es) | 1988-03-24 |
| IL71983A0 (en) | 1984-09-30 |
| JPH0526508B2 (ja) | 1993-04-16 |
| AU2358688A (en) | 1989-01-12 |
| AU2883384A (en) | 1984-12-06 |
| NO842168L (no) | 1984-12-03 |
| PL247978A1 (en) | 1985-04-24 |
| EP0132534B1 (en) | 1991-07-24 |
| KR850000960A (ko) | 1985-03-14 |
| JPS605167A (ja) | 1985-01-11 |
| BR8402614A (pt) | 1985-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4685900A (en) | Therapeutic device | |
| DE3885461T2 (de) | Biospezifische polymere. | |
| US4687808A (en) | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors | |
| DE3105768C2 (de) | Verwendung eines Trägers für die Immobilisierung von bioaktiven Materialien | |
| US5795483A (en) | Method of separating leukocytes from blood cells using a leukodepletion filter | |
| DE3412616A1 (de) | Adsorbens fuer autoantikoerper- und immunkomplexe, dieses enthaltende adsorptionsvorrichtung und dieses enthaltender blutreinigungsapparat | |
| DE3115608A1 (de) | Saeule fuer die adsorption von blutproteinen | |
| DE68910175T2 (de) | Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut. | |
| DD220500A5 (de) | Vorrichtung fuer die extrakorporale behandlung von erkrankten koerperfluessigkeiten | |
| DE112005001901T5 (de) | Einfangen und entfernen von Biomolekülen aus Körperflüssigkeiten unter Verwendung von partiellen molekularen Abdrücken | |
| DE3889400T2 (de) | Verwendung von Adsorptionsmittel und von Vorrichtung zur Trennung von Autoantikörper. | |
| CH626256A5 (en) | Device for the continuous, extracorporal separation of specific substances from blood | |
| WO1998046648A1 (de) | Interaktionssystem zur präsentation und entfernung von substanzen | |
| EP0103184B1 (en) | Activation of biocompatible terpolymers with biologicals whose binding complements are pathological effectors | |
| DD221367A5 (de) | Verfahren zur herstellung eines biospezifischen polymers | |
| DE69525297T2 (de) | Adsorbens fuer ketoamine enthaltende proteine | |
| DE2532883C2 (de) | Verfahren und Vorrichtung zur selektiven Gewinnung eines Reaktionspartners einer Immunreaktion aus dem strömenden Blut von lebenden Organismen | |
| US20100298753A1 (en) | Targeted apheresis for the treatment of rheumatoid arthritis | |
| CA1217424A (en) | Activation of biocompatible polymers with biologicals whose binding complements are pathological effectors | |
| Marcus et al. | Extracorporeal removal of specific antibodies by hemoperfusion through the immunosorbent agarose‐polyacrolein microsphere beads: Removal of anti‐bovine serum albumin in animals | |
| JPH0120903B2 (ja) | ||
| DE19653669A1 (de) | Adsorptionsmatrix, ihre Herstellung und ihre Verwendung zur Entfernung von Immunglobulinen aus biologischen Flüssigkeiten | |
| JPH0347104B2 (ja) | ||
| JPH0771632B2 (ja) | 吸着体およびそれを用いた除去装置 | |
| DE29622239U1 (de) | Spezifische Adsorptionsmatrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |